Changes in characteristics and outcomes of critically ill COVID-19 patients in Tyrol (Austria) over 1 year.


Journal

Wiener klinische Wochenschrift
ISSN: 1613-7671
Titre abrégé: Wien Klin Wochenschr
Pays: Austria
ID NLM: 21620870R

Informations de publication

Date de publication:
Dec 2021
Historique:
received: 28 06 2021
accepted: 25 08 2021
pubmed: 19 10 2021
medline: 17 12 2021
entrez: 18 10 2021
Statut: ppublish

Résumé

Widely varying mortality rates of critically ill Coronavirus disease 19 (COVID-19) patients in the world highlighted the need for local surveillance of baseline characteristics, treatment strategies and outcome. We compared two periods of the COVID-19 pandemic to identify important differences in characteristics and therapeutic measures and their influence on the outcome of critically ill COVID-19 patients. This multicenter prospective register study included all patients with a SARS-CoV‑2 infection confirmed by polymerase chain reaction, who were treated in 1 of the 12 intensive care units (ICU) from 8 hospitals in Tyrol, Austria during 2 defined periods (1 February 2020 until 17 July: first wave and 18 July 2020 until 22 February 2021: second wave) of the COVID-19 pandemic. Overall, 508 patients were analyzed. The majority (n = 401) presented during the second wave, where the median age was significantly higher (64 years, IQR 54-74 years vs. 72 years, IQR 62-78 years, p < 0.001). Invasive mechanical ventilation was less frequent during the second period (50.5% vs 67.3%, p = 0.003), as was the use of vasopressors (50.3% vs. 69.2%, p = 0.001) and renal replacement therapy (12.0% vs. 19.6%, p = 0.061), which resulted in shorter ICU length of stay (10 days, IQR 5-18 days vs. 18 days, IQR 5-31 days, p < 0.001). Nonetheless, ICU mortality did not change (28.9% vs. 21.5%, p = 0.159) and hospital mortality even increased (22.4% vs. 33.4%, p = 0.039) in the second period. Age, frailty and the number of comorbidities were significant predictors of hospital mortality in a multivariate logistic regression analysis of the overall cohort. Advanced treatment strategies and learning effects over time resulted in reduced rates of mechanical ventilation and vasopressor use in the second wave associated with shorter ICU length of stay. Despite these improvements, age appears to be a dominant factor for hospital mortality in critically ill COVID-19 patients.

Sections du résumé

BACKGROUND BACKGROUND
Widely varying mortality rates of critically ill Coronavirus disease 19 (COVID-19) patients in the world highlighted the need for local surveillance of baseline characteristics, treatment strategies and outcome. We compared two periods of the COVID-19 pandemic to identify important differences in characteristics and therapeutic measures and their influence on the outcome of critically ill COVID-19 patients.
METHODS METHODS
This multicenter prospective register study included all patients with a SARS-CoV‑2 infection confirmed by polymerase chain reaction, who were treated in 1 of the 12 intensive care units (ICU) from 8 hospitals in Tyrol, Austria during 2 defined periods (1 February 2020 until 17 July: first wave and 18 July 2020 until 22 February 2021: second wave) of the COVID-19 pandemic.
RESULTS RESULTS
Overall, 508 patients were analyzed. The majority (n = 401) presented during the second wave, where the median age was significantly higher (64 years, IQR 54-74 years vs. 72 years, IQR 62-78 years, p < 0.001). Invasive mechanical ventilation was less frequent during the second period (50.5% vs 67.3%, p = 0.003), as was the use of vasopressors (50.3% vs. 69.2%, p = 0.001) and renal replacement therapy (12.0% vs. 19.6%, p = 0.061), which resulted in shorter ICU length of stay (10 days, IQR 5-18 days vs. 18 days, IQR 5-31 days, p < 0.001). Nonetheless, ICU mortality did not change (28.9% vs. 21.5%, p = 0.159) and hospital mortality even increased (22.4% vs. 33.4%, p = 0.039) in the second period. Age, frailty and the number of comorbidities were significant predictors of hospital mortality in a multivariate logistic regression analysis of the overall cohort.
CONCLUSION CONCLUSIONS
Advanced treatment strategies and learning effects over time resulted in reduced rates of mechanical ventilation and vasopressor use in the second wave associated with shorter ICU length of stay. Despite these improvements, age appears to be a dominant factor for hospital mortality in critically ill COVID-19 patients.

Identifiants

pubmed: 34661740
doi: 10.1007/s00508-021-01945-5
pii: 10.1007/s00508-021-01945-5
pmc: PMC8521508
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1237-1247

Informations de copyright

© 2021. The Author(s).

Références

N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Lancet Respir Med. 2021 May;9(5):e47-e48
pubmed: 33684356
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Wien Klin Wochenschr. 2020 Nov;132(21-22):653-663
pubmed: 33170333
Nat Rev Nephrol. 2020 Dec;16(12):747-764
pubmed: 33060844
JAMA. 2020 Oct 6;324(13):1307-1316
pubmed: 32876695
Crit Care Med. 2021 Jan 1;49(1):102-111
pubmed: 33116052
Dtsch Arztebl Int. 2020 Aug 3;117(31-32):528-533
pubmed: 32900426
Intensive Care Med. 2021 Jan;47(1):60-73
pubmed: 33211135
Crit Care. 2021 Jan 4;25(1):3
pubmed: 33397421
Crit Care. 2013 May 27;17(3):R98
pubmed: 23710662
Anaesthesia. 2020 Oct;75(10):1340-1349
pubmed: 32602561
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Lancet Respir Med. 2020 Sep;8(9):853-862
pubmed: 32735842
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Lancet Respir Med. 2020 Oct;8(10):952-953
pubmed: 32835653
Crit Care. 2021 Apr 19;25(1):149
pubmed: 33874987
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet Reg Health Eur. 2021 May;4:100054
pubmed: 33997829
Nephron Clin Pract. 2012;120(4):c179-84
pubmed: 22890468
Intensive Care Med. 2020 Nov;46(11):2035-2047
pubmed: 33034689
Crit Care. 2017 Jul 12;21(1):184
pubmed: 28701227
Intensive Care Med. 2020 Apr;46(4):654-672
pubmed: 31820034
Intensive Care Med. 2021 May;47(5):538-548
pubmed: 33852032
BMC Infect Dis. 2020 Aug 31;20(1):640
pubmed: 32867706

Auteurs

Timo Mayerhöfer (T)

Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Anichstr. 35, 6020, Innsbruck, Austria.

Sebastian J Klein (SJ)

Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Anichstr. 35, 6020, Innsbruck, Austria.
Doctoral College Medical Law and Healthcare, Faculty of Law, University Innsbruck, Innsbruck, Austria.

Andreas Peer (A)

Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Anichstr. 35, 6020, Innsbruck, Austria.

Fabian Perschinka (F)

Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Anichstr. 35, 6020, Innsbruck, Austria.

Georg F Lehner (GF)

Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Anichstr. 35, 6020, Innsbruck, Austria.

Julia Hasslacher (J)

Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Anichstr. 35, 6020, Innsbruck, Austria.

Romuald Bellmann (R)

Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Anichstr. 35, 6020, Innsbruck, Austria.

Lukas Gasteiger (L)

Department of Anesthesia and Critical Care Medicine, Medical University Innsbruck, Innsbruck, Austria.

Markus Mittermayr (M)

Department of Anesthesia and Critical Care Medicine, Medical University Innsbruck, Innsbruck, Austria.

Stephan Eschertzhuber (S)

Department of Anesthesia and Intensive Care Medicine, Hospital Hall, Hall, Austria.

Simon Mathis (S)

Department of General and Surgical Intensive Care Medicine, Medical University Innsbruck, Innsbruck, Austria.

Anna Fiala (A)

Department of General and Surgical Intensive Care Medicine, Medical University Innsbruck, Innsbruck, Austria.

Dietmar Fries (D)

Department of General and Surgical Intensive Care Medicine, Medical University Innsbruck, Innsbruck, Austria.

Armin Kalenka (A)

Department of Anesthesia and Intensive Care Medicine, Hospital Kufstein, Kufstein, Austria.

Eva Foidl (E)

Department of Anesthesia and Intensive Care Medicine, Hospital Kufstein, Kufstein, Austria.

Walter Hasibeder (W)

Department of Anesthesiology and Critical Care Medicine, Hospital St. Vinzenz Zams, Zams, Austria.

Raimund Helbok (R)

Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.

Lukas Kirchmair (L)

Department of Anesthesia and Critical Care Medicine, Hospital Schwaz, Schwaz, Austria.

Birgit Stögermüller (B)

Department of Anesthesia and Critical Care Medicine, Hospital Schwaz, Schwaz, Austria.

Christoph Krismer (C)

Department of Internal Medicine, Hospital St. Vinzenz Zams, Zams, Austria.

Tatjana Heiner (T)

Department of Anesthesia and Intensive Care Medicine, Hospital Reutte, Reutte, Austria.

Eugen Ladner (E)

Department of Anesthesia and Intensive Care Medicine, Hospital Reutte, Reutte, Austria.

Claudius Thomé (C)

Department of Neurosurgery, Medical University Innsbruck, Innsbruck, Austria.

Christian Preuß-Hernandez (C)

Department of Neurosurgery, Medical University Innsbruck, Innsbruck, Austria.

Andreas Mayr (A)

Department of Anesthesia and Intensive Care Medicine, Hospital Lienz, Lienz, Austria.

Agnes Pechlaner (A)

Department of Internal Medicine, Hospital St. Vinzenz Zams, Zams, Austria.

Miriam Potocnik (M)

Department of Anesthesia and Intensive Care Medicine, Hospital St. Johann in Tyrol, St. Johann in Tyrol, Austria.

Bruno Reitter (B)

Department of Anesthesia and Intensive Care Medicine, Hospital St. Johann in Tyrol, St. Johann in Tyrol, Austria.

Jürgen Brunner (J)

Department of Pediatrics, Medical University Innsbruck, Innsbruck, Austria.

Stefanie Zagitzer-Hofer (S)

Department of Internal Medicine, Hospital Hall, Hall, Austria.

Alexandra Ribitsch (A)

Department of Internal Medicine, Hospital Lienz, Lienz, Austria.

Michael Joannidis (M)

Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Anichstr. 35, 6020, Innsbruck, Austria. michael.joannidis@i-med.ac.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH